OraSure Technologies, Inc.
$3.46-$0.15 (-4.2%)
Last close · Data as of Nov 20, 2026
- Market cap
- $287.1M
- P/E
- -4.2x
- EV / EBITDA
- -1.7x
- Revenue
- $115.0M
- Net margin
- -59.8%
- ROCE
- -18.7%
Price chart
Technical chartScreen technicals →+64.0% over the last year
Daily closes.
Go deeper
Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes
Performance
Price return, before dividends, to the 20 Nov 2026 close.
- 1M
- -7.7%
- 3M
- -7.5%
- 6M
- +12.7%
- 1Y
- +64.0%
- 5Y
- -64.8%
52-week range
Day change -$0.15 (-4.2%) from $3.61 to $3.46 · Last close Nov 20, 2026
Best weekday to invest, historically
The same weekly amount in OSUR, bought on each weekday since 2021.
News & filings
What OraSure Technologies filed, who traded, and what's next
How to read this
"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.
AI Summary
US StockConcernThe company made a net loss of 68.7 million US dollars in fiscal 2025.
Strengths (1)
- Cash on the balance sheet equals 69% of the company's market value.
Prices to the 20 Nov 2026 close · Financial year: fiscal 2025
Rule-based from financial data. Not advice.
About the company
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally.
Read moreShow less
OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, sells, and distributes diagnostic products and specimen collection devices in the United States, Europe, Africa, and internationally. It offers OraQuick Rapid HIV test, OraQuick HIV self-test, OraQuick HIV self-test(international), OraQuick HCV rapid antibody test and self-test, Syphilis health check rapid diagnostic test, OraQuick Ebola rapid antigen test, InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, SickleSCAN test, and OraSure oral fluid collection device for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. The company also provides genomic products under the Oragene and ORAcollect brands for collecting genetic material from human saliva; Colli-Pee collection devices for the volumetric collection of urine samples; and HEMAcollect protein blood collection device. In addition, it provides microbiome products, such as OMNIgene GUT for self-collecting microbial DNA from feces or stool samples for gut microbiome profiling; OMNIgene GUT DNA and RNA collection devices; OMNIgene SALIVA DNA and RNA collection devices; and OMNIgene GUT Dx collection device for collection of human fecal samples and the stabilization of DNA from the bacterial community. Further, it offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests. Additionally, it develops a molecular self-test for chlamydia trachomatis and neisseria gonorrhoeae. It sells its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, commercial and industrial entities, disease risk management, diagnostics, pharmaceutical, biotech, and companion animal, markets. The company was founded in 1987 and is headquartered in Bethlehem, Pennsylvania.
- Sector
- Healthcare
- Shares outstanding
- 70.4M
Key statistics
Screen fundamentals →Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.
Valuation
- Market cap
- $287.1M
- P/E
- -4.2x
- P/B
- 0.8x
- EV / EBITDA
- -1.7x
- EV / Sales
- 0.9x
- P/S
- 2.5x
- 52-week high
- $4.50
- 52-week low
- $2.11
Profitability
- Operating margin
- -59.2%
- Net margin
- -59.8%
- EBITDA margin
- -50.6%
- ROE
- -20.2%
- ROCE
- -18.7%
- ROIC
- -34.8%
- ROA
- -17.0%
- Asset turnover
- 0.29
Growth
- RevenueFY2025, the latest fiscal year in the company's growth history.
- $115.0M
- Revenue growth, 1YFY2025, the latest fiscal year in the company's growth history.
- -38.1%
- Revenue CAGR, 3YFY2025, the latest fiscal year in the company's growth history.
- -33.3%
- Net profit growth, 1YFY2025, the latest fiscal year in the company's growth history.
- 252.5%
- Free cash flowFY2025, the latest fiscal year in the company's growth history.
- -$53.2M
Solvency
- Current ratio
- 6.58
- Debt / Equity
- 0.04
- Debt / Assets
- 0.03
- CFO / Net profit
- 0.71
- Cash / Market cap
- 69.4%
Where the revenue went
FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.
| Line | FY2025 |
|---|---|
| Revenue | $115.0M |
| Cost of revenue | $66.8M |
| Gross profit | $48.2M |
| Operating expenses | $116.3M |
| Research and development | $42.5M |
| Selling, general and administrative | $73.8M |
| Operating income | -$68.1M |
| Interest and other | $3.5M |
| Pretax income | -$64.6M |
| Tax and other | $4.1M |
| Net income | -$68.7M |
Revenue and net profit
Revenue fell 38.1% in FY2025; net profit is the dashed line.
| Date | Revenue | Net profit |
|---|---|---|
| FY2022 | $387.5M | -$17.1M |
| FY2023 | $405.5M | $53.7M |
| FY2024 | $185.8M | -$19.5M |
| FY2025 | $115.0M | -$68.7M |
Cash flows
FY2025: -$49.0M from operations, -$53.2M free after investment (dashed).
| Date | Operating cash flow | Free cash flow |
|---|---|---|
| FY2022 | -$47.2M | -$111.1M |
| FY2023 | $141.6M | $131.3M |
| FY2024 | $27.4M | $23.6M |
| FY2025 | -$49.0M | -$53.2M |
Growth
Latest fiscal year 2025: each figure with its change over the year before.
- Revenue
- $115.0M-38.1%1Y
- EBITDA
- -$58.2M
- Net profit
- -$68.7M
- Cash from operations
- -$49.0M-279.1%1Y
- Free cash flow
- -$53.2M-325.7%1Y
- Revenue CAGR, 3Y
- -33.3%
| Year | Revenue | EBITDA | Net profit | FCF | ROE | Revenue growth 1Y | Net profit growth 1Y |
|---|---|---|---|---|---|---|---|
| FY2025 | $115.0M | -$58.2M | -$68.7M | -$53.2M | -20.2% | -38.1% | +252.5% |
Monthly returns
Month-by-month returns of OSUR across the years, with the seasonal pattern.
Balance sheet
What the company owns and owes at the end of FY2025.
| Line | FY2025 |
|---|---|
| Assets | $403.2M |
| Current assets | $261.9M |
| Non-current assets | $141.3M |
| Liabilities | $62.3M |
| Current liabilities | $39.8M |
| Non-current liabilities | $22.6M |
| Equity | $340.8M |
| Paid-in capital | $531.4M |
| Retained earnings | -$172.2M |
Market cap against peers
8 peers: same sector, nearest by size.
Peers map
Healthcare companies placed by value, growth and quality; OSUR highlighted.
P/E against peers
Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.
Not shown (no positive earnings and no EV / Sales): Eledon Pharmaceuticals, Inc., Anavex Life Sciences Corp.
Peer comparison
Same-sector peers by market cap, with the median.
| Company | Market cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|
| OraSure Technologies, Inc.OSURthis company | $287.1M | -4.2x | 0.8x | -20.2% | -1.7x |
| Electromed, Inc.ELMD | $304.0M | 40.3x | 7.0x | 17.4% | 26.7x |
| Carlsmed, Inc.CARL | $302.8M | -10.2x | 3.1x | -30.0% | -8.4x |
| Alpha Teknova, Inc.TKNO | $291.1M | -16.9x | 4.2x | -25.1% | -30.9x |
| Niagen Bioscience, Inc.NAGE | $278.8M | 16.0x | 3.6x | 22.7% | 13.8x |
| Quantum-Si incorporatedQSI | $278.7M | -2.8x | 1.3x | -46.0% | -2.8x |
| Eledon Pharmaceuticals, Inc.ELDN | $277.9M | -6.1x | 3.4x | -56.3% | -3.1x |
| Entrada Therapeutics, Inc.TRDA | $271.7M | -1.9x | 0.9x | -47.0% | -1.5x |
| Anavex Life Sciences Corp.AVXL | $261.3M | -5.6x | 2.8x | -48.9% | — |
| Peer median | — | -4.2x | 3.2x | -38.0% | -2.8x |
Year-to-date ROI
OSUR since 1 January, against earlier years.
Historical volatility
OSUR's day-to-day swings over 30, 60 and 180 days.
Financial statements
Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.
Consolidated figures in USD, fiscal years, newest first.
Operating margin by fiscal year
| Date | Operating margin |
|---|---|
| FY2022 | -1.4% |
| FY2023 | 10.7% |
| FY2024 | -12.8% |
| FY2025 | -59.2% |
| Line | FY2025 |
|---|---|
| RevenueTotal Revenue | $115.0M |
| Cost of revenueCost Of Revenue | $66.8M |
| Gross profitGross Profit | $48.2M |
| Operating expensesOperating Expense | $116.3M |
| Research and developmentResearch And Development | $42.5M |
| Selling, general and administrativeSelling General And Administration | $73.8M |
| Total expensesTotal Expenses | $183.1M |
| Operating incomeOperating Income | -$68.1M |
| Interest and other | |
| Pretax incomePretax Income | -$64.6M |
| TaxTax Provision | $1.8M |
| Net incomeNet Income | -$68.7M |
| Per share | |
| Supplementary |
| Line | FY2025 |
|---|---|
| AssetsTotal Assets | $403.2M |
| Current assetsCurrent Assets | $261.9M |
| Non-current assetsTotal Non Current Assets | $141.3M |
| LiabilitiesTotal Liabilities Net Minority Interest | $62.3M |
| Current liabilitiesCurrent Liabilities | $39.8M |
| Non-current liabilitiesTotal Non Current Liabilities Net Minority Interest | $22.6M |
| EquityTotal Equity Gross Minority Interest | $340.8M |
| Supplementary |
| Line | FY2025 |
|---|---|
| Operating cash flowOperating Cash Flow | -$49.0M |
| Cash from continuing operationsCash Flow From Continuing Operating Activities | -$49.0M |
| Net income, continuing operationsNet Income From Continuing Operations | -$68.7M |
| Depreciation and amortisationDepreciation And Amortization | $10.0M |
| Depreciation, amortisation and depletionDepreciation Amortization Depletion | $10.0M |
| Depreciation | $10.2M |
| Amortization cash flowAmortization Cash Flow | -$220.0k |
| Amortization of intangiblesAmortization Of Intangibles | -$220.0k |
| Stock-based compensationStock Based Compensation | $10.2M |
| Deferred taxDeferred Tax | $1.9M |
| Deferred income taxDeferred Income Tax | $1.9M |
| Operating gains and lossesOperating Gains Losses | $2.0M |
| Gain loss on sale of PP&EGain Loss On Sale Of PPE | -$720.0k |
| Gain loss on sale of businessGain Loss On Sale Of Business | — |
| Net foreign currency exchange gain lossNet Foreign Currency Exchange Gain Loss | $360.0k |
| Earnings losses from equity investmentsEarnings Losses From Equity Investments | $2.3M |
| Asset impairmentAsset Impairment Charge | $0.00 |
| Provision and write off of assetsProvisionand Write Offof Assets | -$60.0k |
| Change in working capitalChange In Working Capital | -$8.8M |
| Other non-cash itemsOther Non Cash Items | $4.6M |
| Investing cash flowInvesting Cash Flow | -$6.8M |
| Cash from continuing investingCash Flow From Continuing Investing Activities | -$6.8M |
| Capital expenditureCapital Expenditure | -$4.2M |
| Purchase of PP&EPurchase Of PPE | -$4.2M |
| Net PP&E purchases and salesNet PPE Purchase And Sale | -$4.2M |
| AcquisitionsPurchase Of Business | -$3.6M |
| DisposalsSale Of Business | — |
| Net acquisitions and disposalsNet Business Purchase And Sale | -$3.6M |
| Purchase of investmentsPurchase Of Investment | $0.00 |
| Sale of investmentsSale Of Investment | $0.00 |
| Net investment purchases and salesNet Investment Purchase And Sale | $0.00 |
| Purchase of intangiblesPurchase Of Intangibles | — |
| Net intangibles purchases and salesNet Intangibles Purchase And Sale | — |
| Other investing changesNet Other Investing Changes | $1.0M |
| Financing cash flowFinancing Cash Flow | -$16.9M |
| Cash from continuing financingCash Flow From Continuing Financing Activities | -$16.9M |
| Debt repaidRepayment Of Debt | -$60.0k |
| Net debt issuedNet Issuance Payments Of Debt | -$60.0k |
| Short-term debt repaidShort Term Debt Payments | — |
| Net short-term debt issuedNet Short Term Debt Issuance | — |
| Long-term debt repaidLong Term Debt Payments | -$60.0k |
| Net long-term debt issuedNet Long Term Debt Issuance | -$60.0k |
| Shares issuedIssuance Of Capital Stock | — |
| Common stock issuedCommon Stock Issuance | — |
| Net common stock issuedNet Common Stock Issuance | -$16.9M |
| Common stock repurchasedCommon Stock Payments | -$16.9M |
| Share buybacksRepurchase Of Capital Stock | -$16.9M |
| Stock options exercisedProceeds From Stock Option Exercised | $0.00 |
| Other financing chargesNet Other Financing Charges | — |
| Change in cashChanges In Cash | -$72.8M |
| Effect of exchange ratesEffect Of Exchange Rate Changes | 429.0% |
| Cash at the start of the yearBeginning Cash Position | $267.8M |
| Cash at the end of the yearEnd Cash Position | $199.3M |
| Free cash flowFree Cash Flow | -$53.2M |
Learn while you research
Academy chapters picked for OraSure Technologies, Inc. and the metrics on this page.
- 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
- 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
- 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
- 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
- 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read